-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を39ドル引き下げ、70ドルとします。これは、2027年の予想EV/売上高倍率を5.2倍とし、過去10年間の平均倍率7.6倍を下回る水準です。2026年の損失予想を1.50ドルから1.48ドルに、2027年の損失予想を1.48ドルから1.26ドルにそれぞれ引き下げます。チャットアクセスにおける年齢確認のグローバル導入により、コミュニケーションのエンゲージメントが低下しました。この制限は、年齢確認済みのユーザーと未確認のユーザーの両方に影響を与え、コミュニケーションには年齢確認が必須となりました。成人は16歳未満のユーザーとコミュニケーションを取ることができなくなり、年齢層間の交流がさらに制限されています。RBLXはアプリストアの評価が低下していることを確認しており、これは通常アプリストアから発生するオーガニックサインアップの減少の一因となっていると考えています。この変更は、年齢確認と発見アルゴリズムが収益化をより重視するようになったことによるものです。その結果、通期業績見通しが修正され、売上高と予約件数の予想成長率が下方修正されました。
Related Articles
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.